AustralieFrV1, PascalFrancis, Corpus, bibRecord, 001550

Disease-Related Outcomes With Long-Term Follow-Up: An Updated Analysis of the Intergroup Exemestane Study

Identifieur interne : 001550 ( PascalFrancis/Corpus ); précédent : 001549; suivant : 001551

Disease-Related Outcomes With Long-Term Follow-Up: An Updated Analysis of the Intergroup Exemestane Study

Auteurs : Judith M. Bliss ; Lucy S. Kilburn ; Robert E. Coleman ; John F. Forbes ; Alan S. Coates ; Stephen E. Jonas ; Jacek Jassem ; Thierry Delozier ; J Rn Andersen ; Robert Paridaens ; Cornelis J. H. Van De Velde ; Per E. Lonning ; James Morden ; Justine Reise ; Laura Cisar ; Thomas Menschik ; R. Charles Coombes

Source :

Journal of clinical oncology [ 0732-183X ] ; 2012.

RBID : Pascal:12-0121349

Descripteurs français

Pascal (Inist)
- Exémestane, Pronostic, Long terme, Etude longitudinale, Cancérologie, Anticancéreux.

English descriptors

KwdEn :
- Antineoplastic agent, Cancerology, Exemestane, Follow up study, Long term, Prognosis.

Abstract

Purpose Intergroup Exemestane Study (IES), an investigator-led study in 4,724 postmenopausal patients with early-stage breast cancer has demonstrated clinically important benefits from switching adjuvant endocrine therapy after 2 to 3 years of tamoxifen to exemestane. Now, with longer follow-up, a large number of non-breast cancer-related events have been reported. Exploratory analyses describe breast cancer-free survival (BCFS) and explore incidence and patterns of the different competing events. Patients and Methods Patients who were disease-free after 2 to 3 years of adjuvant tamoxifen were randomly assigned to continue tamoxifen or switch to exemestane to complete 5 years of adjuvant endocrine therapy. At this planned analysis, the median follow-up was 91 months. Principal analysis focuses on 4,052 patients with estrogen receptor (ER) -positive and 547 with ER-unknown tumors. Results In all, 930 BCFS events have been reported (exemestane, 423; tamoxifen, 507), giving an unadjusted hazard ratio (HR) of 0.81 (95% CI, 0.71 to 0.92; P = .001) in favor of exemestane in the ER-positive/ER unknown group. Analysis partitioned at 2.5 years after random assignment showed that the on-treatment benefit of switching to exemestane (HR, 0.60; 95% CI, 0.48 to 0.75; P < .001) was not lost post-treatment, but that there was no additional gain once treatment had ceased (HR, 0.94; 95% CI, 0.80 to 1.10; P = .60). Improvement in overall survival was demonstrated, with 352 deaths in the exemestane group versus 405 deaths in the tamoxifen group (HR, 0.86; 95% CI, 0.75 to 0.99; P = .04). Of these, 222 were reported as intercurrent deaths (exemestane, 107; tamoxifen, 115). Conclusion The protective effect of switching to exemestane compared with continuing on tamoxifen on risk of relapse or death was maintained for at least 5 years post-treatment and was associated with a continuing beneficial impact on overall survival.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0732-183X`
A03		`1`		`@0 J. clin. oncol.`
A05				`@2 30`
A06				`@2 7`
A08	`01`	`1`	`ENG`	`@1 Disease-Related Outcomes With Long-Term Follow-Up: An Updated Analysis of the Intergroup Exemestane Study`
A11	`01`	`1`		`@1 BLISS (Judith M.)`
A11	`02`	`1`		`@1 KILBURN (Lucy S.)`
A11	`03`	`1`		`@1 COLEMAN (Robert E.)`
A11	`04`	`1`		`@1 FORBES (John F.)`
A11	`05`	`1`		`@1 COATES (Alan S.)`
A11	`06`	`1`		`@1 JONAS (Stephen E.)`
A11	`07`	`1`		`@1 JASSEM (Jacek)`
A11	`08`	`1`		`@1 DELOZIER (Thierry)`
A11	`09`	`1`		`@1 ANDERSEN (Jørn)`
A11	`10`	`1`		`@1 PARIDAENS (Robert)`
A11	`11`	`1`		`@1 DE VELDE (Cornelis J. H. Van)`
A11	`12`	`1`		`@1 LONNING (Per E.)`
A11	`13`	`1`		`@1 MORDEN (James)`
A11	`14`	`1`		`@1 REISE (Justine)`
A11	`15`	`1`		`@1 CISAR (Laura)`
A11	`16`	`1`		`@1 MENSCHIK (Thomas)`
A11	`17`	`1`		`@1 COOMBES (R. Charles)`
A14	`01`			`@1 The Institute of Cancer Research @2 Sutton @3 GBR @Z 1 aut. @Z 2 aut. @Z 13 aut.`
A14	`02`			`@1 Weston Park Hospital @2 Sheffield @3 GBR @Z 3 aut.`
A14	`03`			`@1 Justine Reise and R. Charles Coombes, Imperial College London @2 London @3 GBR @Z 14 aut. @Z 17 aut.`
A14	`04`			`@1 University of Newcastle, Newcastle Mater Hospital @2 Newcastle, New South Wales @3 AUS @Z 4 aut.`
A14	`05`			`@1 International Breast Cancer Study Group @2 Bern @3 CHE @Z 5 aut.`
A14	`06`			`@1 University of Sydney @2 Sydney @3 AUS @Z 5 aut.`
A14	`07`			`@1 US Oncology Research @2 Houston, TX @3 USA @Z 6 aut.`
A14	`08`			`@1 Medical University of Gdansk @2 Gdansk @3 POL @Z 7 aut.`
A14	`09`			`@1 Centre Francois Baclesse @2 Caen @3 FRA @Z 8 aut.`
A14	`10`			`@1 Pfizer Oncology Europe @2 Paris @3 FRA @Z 16 aut.`
A14	`11`			`@1 Aarhus University Hospital @2 Aarhus @3 DNK @Z 9 aut.`
A14	`12`			`@1 Universitair Ziekenhuis Gasthuisberg @2 Leuven @3 BEL @Z 10 aut.`
A14	`13`			`@1 Leiden University Medical Centre @2 Leiden @3 NLD @Z 11 aut.`
A14	`14`			`@1 University of Bergen and Haukeland University Hospital @2 Bergen @3 NOR @Z 12 aut.`
A14	`15`			`@1 Pfizer @2 New York, NY @3 USA @Z 15 aut.`
A20				`@1 709-717`
A21				`@1 2012`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 20094 @5 354000508401810090`
A44				`@0 0000 @1 © 2012 INIST-CNRS. All rights reserved.`
A45				`@0 16 ref.`
A47	`01`	`1`		`@0 12-0121349`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Journal of clinical oncology`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 Purpose Intergroup Exemestane Study (IES), an investigator-led study in 4,724 postmenopausal patients with early-stage breast cancer has demonstrated clinically important benefits from switching adjuvant endocrine therapy after 2 to 3 years of tamoxifen to exemestane. Now, with longer follow-up, a large number of non-breast cancer-related events have been reported. Exploratory analyses describe breast cancer-free survival (BCFS) and explore incidence and patterns of the different competing events. Patients and Methods Patients who were disease-free after 2 to 3 years of adjuvant tamoxifen were randomly assigned to continue tamoxifen or switch to exemestane to complete 5 years of adjuvant endocrine therapy. At this planned analysis, the median follow-up was 91 months. Principal analysis focuses on 4,052 patients with estrogen receptor (ER) -positive and 547 with ER-unknown tumors. Results In all, 930 BCFS events have been reported (exemestane, 423; tamoxifen, 507), giving an unadjusted hazard ratio (HR) of 0.81 (95% CI, 0.71 to 0.92; P = .001) in favor of exemestane in the ER-positive/ER unknown group. Analysis partitioned at 2.5 years after random assignment showed that the on-treatment benefit of switching to exemestane (HR, 0.60; 95% CI, 0.48 to 0.75; P < .001) was not lost post-treatment, but that there was no additional gain once treatment had ceased (HR, 0.94; 95% CI, 0.80 to 1.10; P = .60). Improvement in overall survival was demonstrated, with 352 deaths in the exemestane group versus 405 deaths in the tamoxifen group (HR, 0.86; 95% CI, 0.75 to 0.99; P = .04). Of these, 222 were reported as intercurrent deaths (exemestane, 107; tamoxifen, 115). Conclusion The protective effect of switching to exemestane compared with continuing on tamoxifen on risk of relapse or death was maintained for at least 5 years post-treatment and was associated with a continuing beneficial impact on overall survival.
C02	`01`	`X`		`@0 002B04`
C03	`01`	`X`	`FRE`	`@0 Exémestane @2 NK @2 FR @5 01`
C03	`01`	`X`	`ENG`	`@0 Exemestane @2 NK @2 FR @5 01`
C03	`01`	`X`	`SPA`	`@0 Exemestano @2 NK @2 FR @5 01`
C03	`02`	`X`	`FRE`	`@0 Pronostic @5 02`
C03	`02`	`X`	`ENG`	`@0 Prognosis @5 02`
C03	`02`	`X`	`SPA`	`@0 Pronóstico @5 02`
C03	`03`	`X`	`FRE`	`@0 Long terme @5 03`
C03	`03`	`X`	`ENG`	`@0 Long term @5 03`
C03	`03`	`X`	`SPA`	`@0 Largo plazo @5 03`
C03	`04`	`X`	`FRE`	`@0 Etude longitudinale @5 05`
C03	`04`	`X`	`ENG`	`@0 Follow up study @5 05`
C03	`04`	`X`	`SPA`	`@0 Estudio longitudinal @5 05`
C03	`05`	`X`	`FRE`	`@0 Cancérologie @5 06`
C03	`05`	`X`	`ENG`	`@0 Cancerology @5 06`
C03	`05`	`X`	`SPA`	`@0 Cancerología @5 06`
C03	`06`	`X`	`FRE`	`@0 Anticancéreux @5 25`
C03	`06`	`X`	`ENG`	`@0 Antineoplastic agent @5 25`
C03	`06`	`X`	`SPA`	`@0 Anticanceroso @5 25`
C07	`01`	`X`	`FRE`	`@0 Dérivé de l'androstane @2 FR @5 37`
C07	`01`	`X`	`ENG`	`@0 Androstane derivatives @2 FR @5 37`
C07	`01`	`X`	`SPA`	`@0 Androstano derivado @2 FR @5 37`
C07	`02`	`X`	`FRE`	`@0 Estrogen synthase @2 FE @5 38`
C07	`02`	`X`	`ENG`	`@0 Estrogen synthase @2 FE @5 38`
C07	`02`	`X`	`SPA`	`@0 Estrogen synthase @2 FE @5 38`
C07	`03`	`X`	`FRE`	`@0 Enzyme @2 FE`
C07	`03`	`X`	`ENG`	`@0 Enzyme @2 FE`
C07	`03`	`X`	`SPA`	`@0 Enzima @2 FE`
C07	`04`	`X`	`FRE`	`@0 Inhibiteur enzyme @5 39`
C07	`04`	`X`	`ENG`	`@0 Enzyme inhibitor @5 39`
C07	`04`	`X`	`SPA`	`@0 Inhibidor enzima @5 39`
C07	`05`	`X`	`FRE`	`@0 Stéroïde @5 40`
C07	`05`	`X`	`ENG`	`@0 Steroid @5 40`
C07	`05`	`X`	`SPA`	`@0 Esteroide @5 40`
C07	`06`	`X`	`FRE`	`@0 Inhibiteur de l'aromatase @5 41`
C07	`06`	`X`	`ENG`	`@0 Aromatase inhibitor @5 41`
C07	`06`	`X`	`SPA`	`@0 Inhibidor aromatase @5 41`
N21				`@1 093`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Format Inist (serveur)

NO :	PASCAL 12-0121349 INIST
ET :	Disease-Related Outcomes With Long-Term Follow-Up: An Updated Analysis of the Intergroup Exemestane Study
AU :	BLISS (Judith M.); KILBURN (Lucy S.); COLEMAN (Robert E.); FORBES (John F.); COATES (Alan S.); JONAS (Stephen E.); JASSEM (Jacek); DELOZIER (Thierry); ANDERSEN (Jørn); PARIDAENS (Robert); DE VELDE (Cornelis J. H. Van); LONNING (Per E.); MORDEN (James); REISE (Justine); CISAR (Laura); MENSCHIK (Thomas); COOMBES (R. Charles)
AF :	The Institute of Cancer Research/Sutton/Royaume-Uni (1 aut., 2 aut., 13 aut.); Weston Park Hospital/Sheffield/Royaume-Uni (3 aut.); Justine Reise and R. Charles Coombes, Imperial College London/London/Royaume-Uni (14 aut., 17 aut.); University of Newcastle, Newcastle Mater Hospital/Newcastle, New South Wales/Australie (4 aut.); International Breast Cancer Study Group/Bern/Suisse (5 aut.); University of Sydney/Sydney/Australie (5 aut.); US Oncology Research/Houston, TX/Etats-Unis (6 aut.); Medical University of Gdansk/Gdansk/Pologne (7 aut.); Centre Francois Baclesse/Caen/France (8 aut.); Pfizer Oncology Europe/Paris/France (16 aut.); Aarhus University Hospital/Aarhus/Danemark (9 aut.); Universitair Ziekenhuis Gasthuisberg/Leuven/Belgique (10 aut.); Leiden University Medical Centre/Leiden/Pays-Bas (11 aut.); University of Bergen and Haukeland University Hospital/Bergen/Norvège (12 aut.); Pfizer/New York, NY/Etats-Unis (15 aut.)
DT :	Publication en série; Niveau analytique
SO :	Journal of clinical oncology; ISSN 0732-183X; Etats-Unis; Da. 2012; Vol. 30; No. 7; Pp. 709-717; Bibl. 16 ref.
LA :	Anglais
EA :	Purpose Intergroup Exemestane Study (IES), an investigator-led study in 4,724 postmenopausal patients with early-stage breast cancer has demonstrated clinically important benefits from switching adjuvant endocrine therapy after 2 to 3 years of tamoxifen to exemestane. Now, with longer follow-up, a large number of non-breast cancer-related events have been reported. Exploratory analyses describe breast cancer-free survival (BCFS) and explore incidence and patterns of the different competing events. Patients and Methods Patients who were disease-free after 2 to 3 years of adjuvant tamoxifen were randomly assigned to continue tamoxifen or switch to exemestane to complete 5 years of adjuvant endocrine therapy. At this planned analysis, the median follow-up was 91 months. Principal analysis focuses on 4,052 patients with estrogen receptor (ER) -positive and 547 with ER-unknown tumors. Results In all, 930 BCFS events have been reported (exemestane, 423; tamoxifen, 507), giving an unadjusted hazard ratio (HR) of 0.81 (95% CI, 0.71 to 0.92; P = .001) in favor of exemestane in the ER-positive/ER unknown group. Analysis partitioned at 2.5 years after random assignment showed that the on-treatment benefit of switching to exemestane (HR, 0.60; 95% CI, 0.48 to 0.75; P < .001) was not lost post-treatment, but that there was no additional gain once treatment had ceased (HR, 0.94; 95% CI, 0.80 to 1.10; P = .60). Improvement in overall survival was demonstrated, with 352 deaths in the exemestane group versus 405 deaths in the tamoxifen group (HR, 0.86; 95% CI, 0.75 to 0.99; P = .04). Of these, 222 were reported as intercurrent deaths (exemestane, 107; tamoxifen, 115). Conclusion The protective effect of switching to exemestane compared with continuing on tamoxifen on risk of relapse or death was maintained for at least 5 years post-treatment and was associated with a continuing beneficial impact on overall survival.
CC :	002B04
FD :	Exémestane; Pronostic; Long terme; Etude longitudinale; Cancérologie; Anticancéreux
FG :	Dérivé de l'androstane; Estrogen synthase; Enzyme; Inhibiteur enzyme; Stéroïde; Inhibiteur de l'aromatase
ED :	Exemestane; Prognosis; Long term; Follow up study; Cancerology; Antineoplastic agent
EG :	Androstane derivatives; Estrogen synthase; Enzyme; Enzyme inhibitor; Steroid; Aromatase inhibitor
SD :	Exemestano; Pronóstico; Largo plazo; Estudio longitudinal; Cancerología; Anticanceroso
LO :	INIST-20094.354000508401810090
ID :	12-0121349

Links to Exploration step

Pascal:12-0121349

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Disease-Related Outcomes With Long-Term Follow-Up: An Updated Analysis of the Intergroup Exemestane Study</title>
<author><name sortKey="Bliss, Judith M" sort="Bliss, Judith M" uniqKey="Bliss J" first="Judith M." last="Bliss">Judith M. Bliss</name>
<affiliation><inist:fA14 i1="01"><s1>The Institute of Cancer Research</s1>
<s2>Sutton</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Kilburn, Lucy S" sort="Kilburn, Lucy S" uniqKey="Kilburn L" first="Lucy S." last="Kilburn">Lucy S. Kilburn</name>
<affiliation><inist:fA14 i1="01"><s1>The Institute of Cancer Research</s1>
<s2>Sutton</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Coleman, Robert E" sort="Coleman, Robert E" uniqKey="Coleman R" first="Robert E." last="Coleman">Robert E. Coleman</name>
<affiliation><inist:fA14 i1="02"><s1>Weston Park Hospital</s1>
<s2>Sheffield</s2>
<s3>GBR</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Forbes, John F" sort="Forbes, John F" uniqKey="Forbes J" first="John F." last="Forbes">John F. Forbes</name>
<affiliation><inist:fA14 i1="04"><s1>University of Newcastle, Newcastle Mater Hospital</s1>
<s2>Newcastle, New South Wales</s2>
<s3>AUS</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Coates, Alan S" sort="Coates, Alan S" uniqKey="Coates A" first="Alan S." last="Coates">Alan S. Coates</name>
<affiliation><inist:fA14 i1="05"><s1>International Breast Cancer Study Group</s1>
<s2>Bern</s2>
<s3>CHE</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="06"><s1>University of Sydney</s1>
<s2>Sydney</s2>
<s3>AUS</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Jonas, Stephen E" sort="Jonas, Stephen E" uniqKey="Jonas S" first="Stephen E." last="Jonas">Stephen E. Jonas</name>
<affiliation><inist:fA14 i1="07"><s1>US Oncology Research</s1>
<s2>Houston, TX</s2>
<s3>USA</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Jassem, Jacek" sort="Jassem, Jacek" uniqKey="Jassem J" first="Jacek" last="Jassem">Jacek Jassem</name>
<affiliation><inist:fA14 i1="08"><s1>Medical University of Gdansk</s1>
<s2>Gdansk</s2>
<s3>POL</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Delozier, Thierry" sort="Delozier, Thierry" uniqKey="Delozier T" first="Thierry" last="Delozier">Thierry Delozier</name>
<affiliation><inist:fA14 i1="09"><s1>Centre Francois Baclesse</s1>
<s2>Caen</s2>
<s3>FRA</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Andersen, J Rn" sort="Andersen, J Rn" uniqKey="Andersen J" first="J Rn" last="Andersen">J Rn Andersen</name>
<affiliation><inist:fA14 i1="11"><s1>Aarhus University Hospital</s1>
<s2>Aarhus</s2>
<s3>DNK</s3>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Paridaens, Robert" sort="Paridaens, Robert" uniqKey="Paridaens R" first="Robert" last="Paridaens">Robert Paridaens</name>
<affiliation><inist:fA14 i1="12"><s1>Universitair Ziekenhuis Gasthuisberg</s1>
<s2>Leuven</s2>
<s3>BEL</s3>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="De Velde, Cornelis J H Van" sort="De Velde, Cornelis J H Van" uniqKey="De Velde C" first="Cornelis J. H. Van" last="De Velde">Cornelis J. H. Van De Velde</name>
<affiliation><inist:fA14 i1="13"><s1>Leiden University Medical Centre</s1>
<s2>Leiden</s2>
<s3>NLD</s3>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Lonning, Per E" sort="Lonning, Per E" uniqKey="Lonning P" first="Per E." last="Lonning">Per E. Lonning</name>
<affiliation><inist:fA14 i1="14"><s1>University of Bergen and Haukeland University Hospital</s1>
<s2>Bergen</s2>
<s3>NOR</s3>
<sZ>12 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Morden, James" sort="Morden, James" uniqKey="Morden J" first="James" last="Morden">James Morden</name>
<affiliation><inist:fA14 i1="01"><s1>The Institute of Cancer Research</s1>
<s2>Sutton</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Reise, Justine" sort="Reise, Justine" uniqKey="Reise J" first="Justine" last="Reise">Justine Reise</name>
<affiliation><inist:fA14 i1="03"><s1>Justine Reise and R. Charles Coombes, Imperial College London</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>14 aut.</sZ>
<sZ>17 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Cisar, Laura" sort="Cisar, Laura" uniqKey="Cisar L" first="Laura" last="Cisar">Laura Cisar</name>
<affiliation><inist:fA14 i1="15"><s1>Pfizer</s1>
<s2>New York, NY</s2>
<s3>USA</s3>
<sZ>15 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Menschik, Thomas" sort="Menschik, Thomas" uniqKey="Menschik T" first="Thomas" last="Menschik">Thomas Menschik</name>
<affiliation><inist:fA14 i1="10"><s1>Pfizer Oncology Europe</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>16 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Coombes, R Charles" sort="Coombes, R Charles" uniqKey="Coombes R" first="R. Charles" last="Coombes">R. Charles Coombes</name>
<affiliation><inist:fA14 i1="03"><s1>Justine Reise and R. Charles Coombes, Imperial College London</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>14 aut.</sZ>
<sZ>17 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">12-0121349</idno>
<date when="2012">2012</date>
<idno type="stanalyst">PASCAL 12-0121349 INIST</idno>
<idno type="RBID">Pascal:12-0121349</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001550</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Disease-Related Outcomes With Long-Term Follow-Up: An Updated Analysis of the Intergroup Exemestane Study</title>
<author><name sortKey="Bliss, Judith M" sort="Bliss, Judith M" uniqKey="Bliss J" first="Judith M." last="Bliss">Judith M. Bliss</name>
<affiliation><inist:fA14 i1="01"><s1>The Institute of Cancer Research</s1>
<s2>Sutton</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Kilburn, Lucy S" sort="Kilburn, Lucy S" uniqKey="Kilburn L" first="Lucy S." last="Kilburn">Lucy S. Kilburn</name>
<affiliation><inist:fA14 i1="01"><s1>The Institute of Cancer Research</s1>
<s2>Sutton</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Coleman, Robert E" sort="Coleman, Robert E" uniqKey="Coleman R" first="Robert E." last="Coleman">Robert E. Coleman</name>
<affiliation><inist:fA14 i1="02"><s1>Weston Park Hospital</s1>
<s2>Sheffield</s2>
<s3>GBR</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Forbes, John F" sort="Forbes, John F" uniqKey="Forbes J" first="John F." last="Forbes">John F. Forbes</name>
<affiliation><inist:fA14 i1="04"><s1>University of Newcastle, Newcastle Mater Hospital</s1>
<s2>Newcastle, New South Wales</s2>
<s3>AUS</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Coates, Alan S" sort="Coates, Alan S" uniqKey="Coates A" first="Alan S." last="Coates">Alan S. Coates</name>
<affiliation><inist:fA14 i1="05"><s1>International Breast Cancer Study Group</s1>
<s2>Bern</s2>
<s3>CHE</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="06"><s1>University of Sydney</s1>
<s2>Sydney</s2>
<s3>AUS</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Jonas, Stephen E" sort="Jonas, Stephen E" uniqKey="Jonas S" first="Stephen E." last="Jonas">Stephen E. Jonas</name>
<affiliation><inist:fA14 i1="07"><s1>US Oncology Research</s1>
<s2>Houston, TX</s2>
<s3>USA</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Jassem, Jacek" sort="Jassem, Jacek" uniqKey="Jassem J" first="Jacek" last="Jassem">Jacek Jassem</name>
<affiliation><inist:fA14 i1="08"><s1>Medical University of Gdansk</s1>
<s2>Gdansk</s2>
<s3>POL</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Delozier, Thierry" sort="Delozier, Thierry" uniqKey="Delozier T" first="Thierry" last="Delozier">Thierry Delozier</name>
<affiliation><inist:fA14 i1="09"><s1>Centre Francois Baclesse</s1>
<s2>Caen</s2>
<s3>FRA</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Andersen, J Rn" sort="Andersen, J Rn" uniqKey="Andersen J" first="J Rn" last="Andersen">J Rn Andersen</name>
<affiliation><inist:fA14 i1="11"><s1>Aarhus University Hospital</s1>
<s2>Aarhus</s2>
<s3>DNK</s3>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Paridaens, Robert" sort="Paridaens, Robert" uniqKey="Paridaens R" first="Robert" last="Paridaens">Robert Paridaens</name>
<affiliation><inist:fA14 i1="12"><s1>Universitair Ziekenhuis Gasthuisberg</s1>
<s2>Leuven</s2>
<s3>BEL</s3>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="De Velde, Cornelis J H Van" sort="De Velde, Cornelis J H Van" uniqKey="De Velde C" first="Cornelis J. H. Van" last="De Velde">Cornelis J. H. Van De Velde</name>
<affiliation><inist:fA14 i1="13"><s1>Leiden University Medical Centre</s1>
<s2>Leiden</s2>
<s3>NLD</s3>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Lonning, Per E" sort="Lonning, Per E" uniqKey="Lonning P" first="Per E." last="Lonning">Per E. Lonning</name>
<affiliation><inist:fA14 i1="14"><s1>University of Bergen and Haukeland University Hospital</s1>
<s2>Bergen</s2>
<s3>NOR</s3>
<sZ>12 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Morden, James" sort="Morden, James" uniqKey="Morden J" first="James" last="Morden">James Morden</name>
<affiliation><inist:fA14 i1="01"><s1>The Institute of Cancer Research</s1>
<s2>Sutton</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Reise, Justine" sort="Reise, Justine" uniqKey="Reise J" first="Justine" last="Reise">Justine Reise</name>
<affiliation><inist:fA14 i1="03"><s1>Justine Reise and R. Charles Coombes, Imperial College London</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>14 aut.</sZ>
<sZ>17 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Cisar, Laura" sort="Cisar, Laura" uniqKey="Cisar L" first="Laura" last="Cisar">Laura Cisar</name>
<affiliation><inist:fA14 i1="15"><s1>Pfizer</s1>
<s2>New York, NY</s2>
<s3>USA</s3>
<sZ>15 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Menschik, Thomas" sort="Menschik, Thomas" uniqKey="Menschik T" first="Thomas" last="Menschik">Thomas Menschik</name>
<affiliation><inist:fA14 i1="10"><s1>Pfizer Oncology Europe</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>16 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Coombes, R Charles" sort="Coombes, R Charles" uniqKey="Coombes R" first="R. Charles" last="Coombes">R. Charles Coombes</name>
<affiliation><inist:fA14 i1="03"><s1>Justine Reise and R. Charles Coombes, Imperial College London</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>14 aut.</sZ>
<sZ>17 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Journal of clinical oncology</title>
<title level="j" type="abbreviated">J. clin. oncol.</title>
<idno type="ISSN">0732-183X</idno>
<imprint><date when="2012">2012</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Journal of clinical oncology</title>
<title level="j" type="abbreviated">J. clin. oncol.</title>
<idno type="ISSN">0732-183X</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antineoplastic agent</term>
<term>Cancerology</term>
<term>Exemestane</term>
<term>Follow up study</term>
<term>Long term</term>
<term>Prognosis</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Exémestane</term>
<term>Pronostic</term>
<term>Long terme</term>
<term>Etude longitudinale</term>
<term>Cancérologie</term>
<term>Anticancéreux</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Purpose Intergroup Exemestane Study (IES), an investigator-led study in 4,724 postmenopausal patients with early-stage breast cancer has demonstrated clinically important benefits from switching adjuvant endocrine therapy after 2 to 3 years of tamoxifen to exemestane. Now, with longer follow-up, a large number of non-breast cancer-related events have been reported. Exploratory analyses describe breast cancer-free survival (BCFS) and explore incidence and patterns of the different competing events. Patients and Methods Patients who were disease-free after 2 to 3 years of adjuvant tamoxifen were randomly assigned to continue tamoxifen or switch to exemestane to complete 5 years of adjuvant endocrine therapy. At this planned analysis, the median follow-up was 91 months. Principal analysis focuses on 4,052 patients with estrogen receptor (ER) -positive and 547 with ER-unknown tumors. Results In all, 930 BCFS events have been reported (exemestane, 423; tamoxifen, 507), giving an unadjusted hazard ratio (HR) of 0.81 (95% CI, 0.71 to 0.92; P = .001) in favor of exemestane in the ER-positive/ER unknown group. Analysis partitioned at 2.5 years after random assignment showed that the on-treatment benefit of switching to exemestane (HR, 0.60; 95% CI, 0.48 to 0.75; P < .001) was not lost post-treatment, but that there was no additional gain once treatment had ceased (HR, 0.94; 95% CI, 0.80 to 1.10; P = .60). Improvement in overall survival was demonstrated, with 352 deaths in the exemestane group versus 405 deaths in the tamoxifen group (HR, 0.86; 95% CI, 0.75 to 0.99; P = .04). Of these, 222 were reported as intercurrent deaths (exemestane, 107; tamoxifen, 115). Conclusion The protective effect of switching to exemestane compared with continuing on tamoxifen on risk of relapse or death was maintained for at least 5 years post-treatment and was associated with a continuing beneficial impact on overall survival.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0732-183X</s0>
</fA01>
<fA03 i2="1"><s0>J. clin. oncol.</s0>
</fA03>
<fA05><s2>30</s2>
</fA05>
<fA06><s2>7</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Disease-Related Outcomes With Long-Term Follow-Up: An Updated Analysis of the Intergroup Exemestane Study</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>BLISS (Judith M.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>KILBURN (Lucy S.)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>COLEMAN (Robert E.)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>FORBES (John F.)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>COATES (Alan S.)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>JONAS (Stephen E.)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>JASSEM (Jacek)</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>DELOZIER (Thierry)</s1>
</fA11>
<fA11 i1="09" i2="1"><s1>ANDERSEN (Jørn)</s1>
</fA11>
<fA11 i1="10" i2="1"><s1>PARIDAENS (Robert)</s1>
</fA11>
<fA11 i1="11" i2="1"><s1>DE VELDE (Cornelis J. H. Van)</s1>
</fA11>
<fA11 i1="12" i2="1"><s1>LONNING (Per E.)</s1>
</fA11>
<fA11 i1="13" i2="1"><s1>MORDEN (James)</s1>
</fA11>
<fA11 i1="14" i2="1"><s1>REISE (Justine)</s1>
</fA11>
<fA11 i1="15" i2="1"><s1>CISAR (Laura)</s1>
</fA11>
<fA11 i1="16" i2="1"><s1>MENSCHIK (Thomas)</s1>
</fA11>
<fA11 i1="17" i2="1"><s1>COOMBES (R. Charles)</s1>
</fA11>
<fA14 i1="01"><s1>The Institute of Cancer Research</s1>
<s2>Sutton</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>13 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Weston Park Hospital</s1>
<s2>Sheffield</s2>
<s3>GBR</s3>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Justine Reise and R. Charles Coombes, Imperial College London</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>14 aut.</sZ>
<sZ>17 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>University of Newcastle, Newcastle Mater Hospital</s1>
<s2>Newcastle, New South Wales</s2>
<s3>AUS</s3>
<sZ>4 aut.</sZ>
</fA14>
<fA14 i1="05"><s1>International Breast Cancer Study Group</s1>
<s2>Bern</s2>
<s3>CHE</s3>
<sZ>5 aut.</sZ>
</fA14>
<fA14 i1="06"><s1>University of Sydney</s1>
<s2>Sydney</s2>
<s3>AUS</s3>
<sZ>5 aut.</sZ>
</fA14>
<fA14 i1="07"><s1>US Oncology Research</s1>
<s2>Houston, TX</s2>
<s3>USA</s3>
<sZ>6 aut.</sZ>
</fA14>
<fA14 i1="08"><s1>Medical University of Gdansk</s1>
<s2>Gdansk</s2>
<s3>POL</s3>
<sZ>7 aut.</sZ>
</fA14>
<fA14 i1="09"><s1>Centre Francois Baclesse</s1>
<s2>Caen</s2>
<s3>FRA</s3>
<sZ>8 aut.</sZ>
</fA14>
<fA14 i1="10"><s1>Pfizer Oncology Europe</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>16 aut.</sZ>
</fA14>
<fA14 i1="11"><s1>Aarhus University Hospital</s1>
<s2>Aarhus</s2>
<s3>DNK</s3>
<sZ>9 aut.</sZ>
</fA14>
<fA14 i1="12"><s1>Universitair Ziekenhuis Gasthuisberg</s1>
<s2>Leuven</s2>
<s3>BEL</s3>
<sZ>10 aut.</sZ>
</fA14>
<fA14 i1="13"><s1>Leiden University Medical Centre</s1>
<s2>Leiden</s2>
<s3>NLD</s3>
<sZ>11 aut.</sZ>
</fA14>
<fA14 i1="14"><s1>University of Bergen and Haukeland University Hospital</s1>
<s2>Bergen</s2>
<s3>NOR</s3>
<sZ>12 aut.</sZ>
</fA14>
<fA14 i1="15"><s1>Pfizer</s1>
<s2>New York, NY</s2>
<s3>USA</s3>
<sZ>15 aut.</sZ>
</fA14>
<fA20><s1>709-717</s1>
</fA20>
<fA21><s1>2012</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20094</s2>
<s5>354000508401810090</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2012 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>16 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>12-0121349</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Journal of clinical oncology</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Purpose Intergroup Exemestane Study (IES), an investigator-led study in 4,724 postmenopausal patients with early-stage breast cancer has demonstrated clinically important benefits from switching adjuvant endocrine therapy after 2 to 3 years of tamoxifen to exemestane. Now, with longer follow-up, a large number of non-breast cancer-related events have been reported. Exploratory analyses describe breast cancer-free survival (BCFS) and explore incidence and patterns of the different competing events. Patients and Methods Patients who were disease-free after 2 to 3 years of adjuvant tamoxifen were randomly assigned to continue tamoxifen or switch to exemestane to complete 5 years of adjuvant endocrine therapy. At this planned analysis, the median follow-up was 91 months. Principal analysis focuses on 4,052 patients with estrogen receptor (ER) -positive and 547 with ER-unknown tumors. Results In all, 930 BCFS events have been reported (exemestane, 423; tamoxifen, 507), giving an unadjusted hazard ratio (HR) of 0.81 (95% CI, 0.71 to 0.92; P = .001) in favor of exemestane in the ER-positive/ER unknown group. Analysis partitioned at 2.5 years after random assignment showed that the on-treatment benefit of switching to exemestane (HR, 0.60; 95% CI, 0.48 to 0.75; P < .001) was not lost post-treatment, but that there was no additional gain once treatment had ceased (HR, 0.94; 95% CI, 0.80 to 1.10; P = .60). Improvement in overall survival was demonstrated, with 352 deaths in the exemestane group versus 405 deaths in the tamoxifen group (HR, 0.86; 95% CI, 0.75 to 0.99; P = .04). Of these, 222 were reported as intercurrent deaths (exemestane, 107; tamoxifen, 115). Conclusion The protective effect of switching to exemestane compared with continuing on tamoxifen on risk of relapse or death was maintained for at least 5 years post-treatment and was associated with a continuing beneficial impact on overall survival.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B04</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Exémestane</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Exemestane</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Exemestano</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Pronostic</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Prognosis</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Pronóstico</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Long terme</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Long term</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Largo plazo</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Etude longitudinale</s0>
<s5>05</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Follow up study</s0>
<s5>05</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Estudio longitudinal</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Cancérologie</s0>
<s5>06</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Cancerology</s0>
<s5>06</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Cancerología</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Anticancéreux</s0>
<s5>25</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Antineoplastic agent</s0>
<s5>25</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Anticanceroso</s0>
<s5>25</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Dérivé de l'androstane</s0>
<s2>FR</s2>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Androstane derivatives</s0>
<s2>FR</s2>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Androstano derivado</s0>
<s2>FR</s2>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Estrogen synthase</s0>
<s2>FE</s2>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Estrogen synthase</s0>
<s2>FE</s2>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Estrogen synthase</s0>
<s2>FE</s2>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Enzyme</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Enzyme</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Enzima</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Inhibiteur enzyme</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Enzyme inhibitor</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Inhibidor enzima</s0>
<s5>39</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Stéroïde</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Steroid</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Esteroide</s0>
<s5>40</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Inhibiteur de l'aromatase</s0>
<s5>41</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Aromatase inhibitor</s0>
<s5>41</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Inhibidor aromatase</s0>
<s5>41</s5>
</fC07>
<fN21><s1>093</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 12-0121349 INIST</NO>
<ET>Disease-Related Outcomes With Long-Term Follow-Up: An Updated Analysis of the Intergroup Exemestane Study</ET>
<AU>BLISS (Judith M.); KILBURN (Lucy S.); COLEMAN (Robert E.); FORBES (John F.); COATES (Alan S.); JONAS (Stephen E.); JASSEM (Jacek); DELOZIER (Thierry); ANDERSEN (Jørn); PARIDAENS (Robert); DE VELDE (Cornelis J. H. Van); LONNING (Per E.); MORDEN (James); REISE (Justine); CISAR (Laura); MENSCHIK (Thomas); COOMBES (R. Charles)</AU>
<AF>The Institute of Cancer Research/Sutton/Royaume-Uni (1 aut., 2 aut., 13 aut.); Weston Park Hospital/Sheffield/Royaume-Uni (3 aut.); Justine Reise and R. Charles Coombes, Imperial College London/London/Royaume-Uni (14 aut., 17 aut.); University of Newcastle, Newcastle Mater Hospital/Newcastle, New South Wales/Australie (4 aut.); International Breast Cancer Study Group/Bern/Suisse (5 aut.); University of Sydney/Sydney/Australie (5 aut.); US Oncology Research/Houston, TX/Etats-Unis (6 aut.); Medical University of Gdansk/Gdansk/Pologne (7 aut.); Centre Francois Baclesse/Caen/France (8 aut.); Pfizer Oncology Europe/Paris/France (16 aut.); Aarhus University Hospital/Aarhus/Danemark (9 aut.); Universitair Ziekenhuis Gasthuisberg/Leuven/Belgique (10 aut.); Leiden University Medical Centre/Leiden/Pays-Bas (11 aut.); University of Bergen and Haukeland University Hospital/Bergen/Norvège (12 aut.); Pfizer/New York, NY/Etats-Unis (15 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Journal of clinical oncology; ISSN 0732-183X; Etats-Unis; Da. 2012; Vol. 30; No. 7; Pp. 709-717; Bibl. 16 ref.</SO>
<LA>Anglais</LA>
<EA>Purpose Intergroup Exemestane Study (IES), an investigator-led study in 4,724 postmenopausal patients with early-stage breast cancer has demonstrated clinically important benefits from switching adjuvant endocrine therapy after 2 to 3 years of tamoxifen to exemestane. Now, with longer follow-up, a large number of non-breast cancer-related events have been reported. Exploratory analyses describe breast cancer-free survival (BCFS) and explore incidence and patterns of the different competing events. Patients and Methods Patients who were disease-free after 2 to 3 years of adjuvant tamoxifen were randomly assigned to continue tamoxifen or switch to exemestane to complete 5 years of adjuvant endocrine therapy. At this planned analysis, the median follow-up was 91 months. Principal analysis focuses on 4,052 patients with estrogen receptor (ER) -positive and 547 with ER-unknown tumors. Results In all, 930 BCFS events have been reported (exemestane, 423; tamoxifen, 507), giving an unadjusted hazard ratio (HR) of 0.81 (95% CI, 0.71 to 0.92; P = .001) in favor of exemestane in the ER-positive/ER unknown group. Analysis partitioned at 2.5 years after random assignment showed that the on-treatment benefit of switching to exemestane (HR, 0.60; 95% CI, 0.48 to 0.75; P < .001) was not lost post-treatment, but that there was no additional gain once treatment had ceased (HR, 0.94; 95% CI, 0.80 to 1.10; P = .60). Improvement in overall survival was demonstrated, with 352 deaths in the exemestane group versus 405 deaths in the tamoxifen group (HR, 0.86; 95% CI, 0.75 to 0.99; P = .04). Of these, 222 were reported as intercurrent deaths (exemestane, 107; tamoxifen, 115). Conclusion The protective effect of switching to exemestane compared with continuing on tamoxifen on risk of relapse or death was maintained for at least 5 years post-treatment and was associated with a continuing beneficial impact on overall survival.</EA>
<CC>002B04</CC>
<FD>Exémestane; Pronostic; Long terme; Etude longitudinale; Cancérologie; Anticancéreux</FD>
<FG>Dérivé de l'androstane; Estrogen synthase; Enzyme; Inhibiteur enzyme; Stéroïde; Inhibiteur de l'aromatase</FG>
<ED>Exemestane; Prognosis; Long term; Follow up study; Cancerology; Antineoplastic agent</ED>
<EG>Androstane derivatives; Estrogen synthase; Enzyme; Enzyme inhibitor; Steroid; Aromatase inhibitor</EG>
<SD>Exemestano; Pronóstico; Largo plazo; Estudio longitudinal; Cancerología; Anticanceroso</SD>
<LO>INIST-20094.354000508401810090</LO>
<ID>12-0121349</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001550 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 001550 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Asie
   |area=    AustralieFrV1
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:12-0121349
   |texte=   Disease-Related Outcomes With Long-Term Follow-Up: An Updated Analysis of the Intergroup Exemestane Study
}}

This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024

	Serveur d'exploration sur les relations entre la France et l'Australie
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur les relations entre la France et l'Australie

Disease-Related Outcomes With Long-Term Follow-Up: An Updated Analysis of the Intergroup Exemestane Study

Disease-Related Outcomes With Long-Term Follow-Up: An Updated Analysis of the Intergroup Exemestane Study

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri